Wedbush Keeps Bicara Therapeutics Outperform, Cuts Target to $24
Wedbush maintained its Outperform rating on Bicara Therapeutics and lowered its price target to $24 from $33.
Related stories
Mondelez Q3 profit exceeds expectations as cost pressures ease
Reuters reports Mondelez International’s third-quarter profit exceeded expectations as cost pressures eased.
M impact | EQUITY | Oct 29, 2026, 09:21 PM UTC
Erie Indemnity Q3 Profit Falls to $181.989 Million
Erie Indemnity reported third-quarter profit of $181.989 million, or $3.48 per share, compared with $182.853 million, or $3.50 per share, a year earlier. Revenue rose, but the repo
M impact | EQUITY | Oct 29, 2026, 09:21 PM UTC
Southern Missouri Bancorp CFO Chkautovich to Resign November 7
CFO Stefan Chkautovich will resign effective November 7 to pursue another professional opportunity. The filing names Funke as principal financial officer.
M impact | EQUITY | Oct 29, 2026, 09:19 PM UTC
Coinbase Q3 transaction revenue is $590 million
M impact | EQUITY | Oct 29, 2026, 09:19 PM UTC
JioBlackRock Broking Appoints Nikhil Dhoka CEO
Nikhil Dhoka, a former Kotak Neo executive, has taken charge as CEO of JioBlackRock Broking, the brokerage arm of the Jio Financial Services–BlackRock joint venture.
M impact | EQUITY | Oct 29, 2026, 09:19 PM UTC
Donaldson Signs Note Purchase Agreement for Up to $1.5 Billion
Donaldson signed a note purchase agreement with institutional investors for up to $1.5 billion.
M impact | EQUITY | Oct 29, 2026, 09:18 PM UTC